mitoxantrone for MS
Selected indexed studies
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. (Lancet Neurol, 2020) [PMID:32199096]
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis. (Cochrane Database Syst Rev, 2023) [PMID:38032059]
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. (Cochrane Database Syst Rev, 2024) [PMID:38174776]
_Worker-drafted node — pending editorial review._
Connections
mitoxantrone for MS is a side effect of
Sources
- [Mitoxantrone]. (2003) pubmed
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. (2020) pubmed
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis. (2023) pubmed
- How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). (2021) pubmed
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. (2024) pubmed
- Mitoxantrone for multiple sclerosis. (2005) pubmed
- Mitoxantrone for multiple sclerosis. (2013) pubmed
- Rationale for the use of mitoxantrone in multiple sclerosis. (2004) pubmed
- Evaluation of mitoxantrone for the treatment of multiple sclerosis. (2000) pubmed
- Is there a new place for mitoxantrone in the treatment of multiple sclerosis? (2020) pubmed